Thrombophilic Evaluation in Patients with Acute Pulmonary Embolism

Abstract

Patients with acute pulmonary embolism (PE) are often tested for thrombophilias, which are hereditary and acquired conditions that predispose to thrombosis. If a hereditary condition is identified, then testing is often performed on members of the patient's family. Testing for these conditions can be complex, as the presence of acute thrombosis and antithrombotic therapies can make the results of many tests unreliable. Many risk factors for thrombosis exist that are not routinely assessed by laboratory testing, and it is likely that many hereditary thrombophilia conditions remain to be discovered. Also, various risk factors for thrombosis interact with one another. Therefore, the results of a laboratory thrombophilia evaluation provide a limited ability to assess a patient or family members' risk for future thrombosis, and such testing usually does not provide information that improves a management decision. Thrombophilia testing is expensive and carries potential risks. This article reviews common thrombophilias, their epidemiology and classification, and timing and technical aspects of accurate testing and provides rational suggestions for the use of thrombophilia testing in five clinical situations: (1) following provoked PE (or other venous thromboembolism), (2) following unprovoked venous thromboembolism, (3) in relatives of patients with thrombosis, (4) in female relatives of patients with thrombosis considering estrogen use, and (5) in female relatives of patients with thrombosis who are considering pregnancy. Published guidelines and guidance statements from professional societies and other groups are also reviewed. Clinicians should carefully consider the relevant risks and benefits before testing patients for thrombophilia. When performed, testing should be timed correctly and care should be taken to properly interpret results. New models that incorporate multiple genetic and clinical markers may improve the utility of testing, but these await further research.

Keywords

thrombophilia - venous thromboembolism - deep vein thrombosis - pulmonary embolism - genetic analysis - antiphospholipid syndrome

• References

• 1 Morange PE, Suchon P, Trégouët DA. Genetics of venous thrombosis: update in 2015. Thromb Haemost 2015; 114 (5) 910-919
• 2 Baglin T, Gray E, Greaves M , et al; British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149 (2) 209-220
• 3 Stevens SM. Role of thrombophilia testing: con. J Thromb Thrombolysis 2015; 39 (3) 379-391
• 4 Jennings I, Kitchen S, Woods TA, Preston FE. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost 2005; 31 (1) 66-72
• 5 Foy P, Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med 2009; 11 (2) 114-128
• 6 Cushman M. Thrombophilia testing in women with venous thrombosis: the 4 P's approach. Clin Chem 2014; 60 (1) 134-137
• 7 Stevens SM, Woller SC, Bauer KA , et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 2016; 41 (1) 154-164
• 8 Nygaard KKBG. Essential thrombophilia: report of five cases. Arch Intern Med 1937; 59: 82-106
• 9 Virchow R. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Germany: Medinger Sohn; 1856
• 10 Bouillaud S. L'obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med 1823; 1: 188-204
• 11 Briggs J. Recurring phlebitis of obscure origins. Johns Hopkins Hosp Bull 1905; 16: 228-233
• 12 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
• 13 Jick H, Slone D, Westerholm B , et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969; 1 (7594): 539-542
• 14 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68 (5) 1370-1373
• 15 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311 (24) 1525-1528
• 16 Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A 1994; 91 (4) 1396-1400
• 17 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-3703
• 18 Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost 2015; 114 (5) 885-889
• 19 Franchini M, Martinelli I, Mannucci PM. Uncertain thrombophilia markers. Thromb Haemost 2016; 115 (1) 25-30
• 20 Freyburger G, Labrouche S, Hubert C, Bauduer F. Haemostaseome-associated SNPs: has the thrombotic phenotype a greater influence than ethnicity? GMT study from Aquitaine including Basque individuals. Thromb Haemost 2015; 113 (1) 66-76
• 21 Zöller B, Li X, Ohlsson H, Ji J, Sundquist J, Sundquist K. Family history of venous thromboembolism as a risk factor and genetic research tool. Thromb Haemost 2015; 114 (5) 890-900
• 22 Tang L, Hu Y. Ethnic diversity in the genetics of venous thromboembolism. Thromb Haemost 2015; 114 (5) 901-909
• 23 Pahus SH, Hansen AT, Hvas AM. Thrombophilia testing in young patients with ischemic stroke. Thromb Res 2016; 137: 108-112
• 24 Wu O, Robertson L, Twaddle S , et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006; 10 (11) 1-110
• 25 Kearon C, Akl EA, Comerota AJ , et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl) e419S-e494S
• 26 Chong LY, Fenu E, Stansby G, Hodgkinson S ; Guideline Development Group. Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. BMJ 2012; 344: e3979
• 27 Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362 (9383): 523-526
• 28 Simone B, De Stefano V, Leoncini E , et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol 2013; 28 (8) 621-647
• 29 Nicolaides A, Hull RD, Fareed J ; Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie. Thrombophilia. Clin Appl Thromb Hemost 2013; 19 (2) 177-187
• 30 Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293 (19) 2352-2361
• 31 Dalen JE. Should patients with venous thromboembolism be screened for thrombophilia?. Am J Med 2008; 121 (6) 458-463
• 32 Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost 2009; 102 (2) 360-370
• 33 Bruzelius M, Ljungqvist M, Bottai M , et al. F11 is associated with recurrent VTE in women. A prospective cohort study. Thromb Haemost 2016; 115 (2) 406-414
• 34 Sundquist K, Wang X, Svensson PJ , et al. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence. Thromb Haemost 2015; 114 (6) 1156-1164
• 35 Szlauer A, Mielimonka A, Głowacki R, Borowczyk K, Stachniuk J, Undas A. Protein N-linked homocysteine is associated with recurrence of venous thromboembolism. Thromb Res 2015; 136 (5) 911-916
• 36 Kooiman J, den Exter PL, Kilicsoy I , et al. Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism. J Thromb Thrombolysis 2015; 40 (3) 323-330
• 37 Campello E, Spiezia L, Radu CM , et al. Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S. Thromb Haemost 2016; 115 (1) 81-88
• 38 Baudouy D, Moceri P, Chiche O , et al. B blood group: a strong risk factor for venous thromboembolism recurrence. Thromb Res 2015; 136 (1) 107-111
• 39 Zhou S, Welsby I. Is ABO blood group truly a risk factor for thrombosis and adverse outcomes?. World J Cardiol 2014; 6 (9) 985-992
• 40 Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC. Body height, mobility, and risk of first and recurrent venous thrombosis. J Thromb Haemost 2015; 13 (4) 548-554
• 41 Lutsey PL, Cushman M, Heckbert SR, Tang W, Folsom AR ; The Longitudinal Study of Thromboembolism Etiology (LITE). Longer legs are associated with greater risk of incident venous thromboembolism independent of total body height. Thromb Haemost 2011; 106 (1) 113-120
• 42 Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28 (3) 370-372
• 43 Oger E, Lacut K, Le Gal G , et al; EDITH (Etude des Déterminants/Interaction de la THrombose veineuse) Collaborative Study Group. Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the E.D.I.TH. study: a hospital-based case-control study. Thromb Res 2007; 120 (2) 207-214
• 44 Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet 2000; 356 (9225): 182-183
• 45 Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41 (1) 92-128
• 46 Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E ; Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med 2007; 146 (11) 761-767
• 47 Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3 (2) 292-299
• 48 Franchini M, Mannucci PM. ABO blood group and thrombotic vascular disease. Thromb Haemost 2014; 112 (6) 1103-1109
• 49 Lijfering WM, Coppens M, Veeger NJ , et al. Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis, and is associated with elevated factor VIII levels. Thromb Res 2008; 123 (2) 244-250
• 50 Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35 (5) 468-477
• 51 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368 (11) 1033-1044
• 52 Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
• 53 Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013; 122 (5) 817-824
• 54 Pengo V, Biasiolo A. The risk of overdiagnosis of antiphospholipid antibody syndrome. Thromb Haemost 2001; 86 (3) 933
• 55 Hillarp A, Gustafsson KM, Faxälv L , et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost 2014; 12 (9) 1545-1553
• 56 Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013; 109 (1) 127-136
• 57 American College of Obstetricians and Gynecologists Women's Health Care Physicians. ACOG Practice Bulletin No. 138: inherited thrombophilias in pregnancy. Obstet Gynecol 2013; 122 (3) 706-717
• 58 Pintao MC, Ribeiro DD, Bezemer ID , et al. Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study. Blood 2013; 122 (18) 3210-3219
• 59 Pengo V, Tripodi A, Reber G , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
• 60 Arachchillage DR, Mackie IJ, Efthymiou M, Isenberg DA, Machin SJ, Cohen H. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 2015; 13 (7) 1264-1273
• 61 Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis 2015; 39 (3) 367-378
• 62 Adcock DM, Gosselin R. Direct oral anticoagulants (DOACs) in the laboratory: 2015 review. Thromb Res 2015; 136 (1) 7-12
• 63 Kearon C, Spencer FA, O'Keeffe D , et al; D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 2015; 162 (1) 27-34
• 64 Reitter-Pfoertner S, Waldhoer T, Mayerhofer M , et al. The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism. Thromb Haemost 2013; 109 (1) 79-84
• 65 Rabinovich A, Cohen JM, Prandoni P, Kahn SR. Association between thrombophilia and the post-thrombotic syndrome: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (1) 14-23
• 66 Kearon C, Akl EA, Ornelas J , et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149 (2) 315-352
• 67 Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014; 123 (12) 1794-1801
• 68 Coppens M, Reijnders JH, Middeldorp S, Doggen CJ, Rosendaal FR. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 2008; 6 (9) 1474-1477
• 69 Hicks LK, Bering H, Carson KR , et al. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Hematology (Am Soc Hematol Educ Program) 2013; 2013: 9-14
• 70 Choosing Wisely. Don't do work up for clotting disorder (order hypercoagulable testing) for patients who develop first episode of deep vein thrombosis (DVT) in the setting of a known cause. Available at http://www.choosingwisely.org/clinician-lists/society-vascular-medicine-clotting-disorder-workup-after-first-episode-of-deep-vein-thrombosis/ . Accessed April 4, 2016
• 71 American Board of Internal Medicine Foundation. Choosing Wisely. Available at http://www.choosingwisely.org/ . Accessed April 4, 2016
• 72 Boutitie F, Pinede L, Schulman S , et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011; 342: d3036
• 73 Baglin T. Unraveling the thrombophilia paradox: from hypercoagulability to the prothrombotic state. J Thromb Haemost 2010; 8 (2) 228-233
• 74 Pernod G, Biron-Andreani C, Morange PE , et al; French group on haemostasis and thrombosis; French Society of vascular medicine. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc 2009; 34 (3) 156-203
• 75 Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA ; ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001; 3 (2) 139-148
• 76 Merriman L, Greaves M. Testing for thrombophilia: an evidence-based approach. Postgrad Med J 2006; 82 (973) 699-704
• 77 Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169 (6) 610-615
• 78 Zöller B, Ohlsson H, Sundquist J, Sundquist K. Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden. Thromb Haemost 2013; 109 (3) 458-463
• 79 Sørensen HT, Riis AH, Diaz LJ, Andersen EW, Baron JA, Andersen PK. Familial risk of venous thromboembolism: a nationwide cohort study. J Thromb Haemost 2011; 9 (2) 320-324
• 80 Couturaud F, Leroyer C, Tromeur C , et al. Factors that predict thrombosis in relatives of patients with venous thromboembolism. Blood 2014; 124 (13) 2124-2130
• 81 Mahmoodi BK, Brouwer JL, Ten Kate MK , et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost 2010; 8 (6) 1193-1200
• 82 Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999; 72 (4) 646-651
• 83 Smith KJ, Monsef BS, Ragni MV. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Thromb Haemost 2008; 100 (3) 447-452
• 84 Middeldorp S. Evidence-based approach to thrombophilia testing. J Thromb Thrombolysis 2011; 31 (3) 275-281
• 85 James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194 (5) 1311-1315
• 86 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO ; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl) e691S-e736S
• 87 Lussana F, Dentali F, Abbate R , et al; Italian Society for Haemostasis and Thrombosis. Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2009; 124 (5) e19-e25
• 88 Pabinger I, Grafenhofer H, Kaider A , et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3 (5) 949-954
• 89 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143 (10) 697-706
• 90 Villani M, Tiscia GL, Margaglione M , et al. Risk of obstetric and thromboembolic complications in family members of women with previous adverse obstetric outcomes carrying common inherited thombophilias. J Thromb Haemost 2012; 10 (2) 223-228
• 91 Rodger MA, Hague WM, Kingdom J , et al; TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 2014; 384 (9955): 1673-1683
• 92 Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2014; 2 (2) CD001689
• 93 Segal JB, Brotman DJ, Necochea AJ , et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009; 301 (23) 2472-2485
• 94 Bank I, Scavenius MP, Büller HR, Middeldorp S. Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res 2004; 113 (1) 7-12
• 95 Cohn DM, Vansenne F, Kaptein AA, De Borgie CA, Middeldorp S. The psychological impact of testing for thrombophilia: a systematic review. J Thromb Haemost 2008; 6 (7) 1099-1104
• 96 Hellmann EA, Leslie ND, Moll S. Knowledge and educational needs of individuals with the factor V Leiden mutation. J Thromb Haemost 2003; 1 (11) 2335-2339
• 97 Duhl AJ, Paidas MJ, Ural SH , et al; Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197 (5) 457.e1-457.e21
• 98 Lockwood C, Wendel G ; Committee on Practice Bulletins—Obstetrics. Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol 2011; 118 (3) 730-740
• 99 McLintock C, Brighton T, Chunilal S , et al; Councils of the Society of Obstetric Medicine of Australia and New Zealand; Australasian Society of Thrombosis and Haemostasis. Recommendations for the prevention of pregnancy-associated venous thromboembolism. Aust N Z J Obstet Gynaecol 2012; 52 (1) 3-13
• 100 MacCallum P, Bowles L, Keeling D. Diagnosis and management of heritable thrombophilias. BMJ 2014; 349: g4387
• 101 Meyer MR, Witt DM, Delate T , et al. Thrombophilia testing patterns amongst patients with acute venous thromboembolism. Thromb Res 2015; 136 (6) 1160-1164
• 102 Rodger MA, Kahn SR, Wells PS , et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179 (5) 417-426
• 103 Tosetto A, Iorio A, Marcucci M , et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10 (6) 1019-1025
• 104 Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121 (14) 1630-1636
• 105 Palareti G, Cosmi B, Legnani C , et al; DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 2014; 124 (2) 196-203
• 106 Cosmi B, Legnani C, Tosetto A , et al; PROLONG Investigators (on behalf of Italian Federation of Anticoagulation Clinics). Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 2010; 115 (3) 481-488
• 107 Eichinger S, Minar E, Bialonczyk C , et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290 (8) 1071-1074
• 108 Castellucci LA, Cameron C, Le Gal G , et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 2014; 312 (11) 1122-1135
• 109 Cohen W, Castelli C, Suchon P , et al. Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-NImes prediction model. J Thromb Haemost 2014; 12: 138-146
• 110 de Haan HG, Bezemer ID, Doggen CJ , et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 2012; 120 (3) 656-663
• 111 Soria JM, Morange PE, Vila J , et al. Multilocus genetic risk scores for venous thromboembolism risk assessment. J Am Heart Assoc 2014; 3 (5) e001060
• 112 Bruzelius M, Bottai M, Sabater-Lleal M , et al. Predicting venous thrombosis in women using a combination of genetic markers and clinical risk factors. J Thromb Haemost 2015; 13 (2) 219-227
• 113 Folsom AR, Tang W, Weng LC , et al. Replication of a genetic risk score for venous thromboembolism in whites but not in African Americans. J Thromb Haemost 2016; 14 (1) 83-88
• 114 Lindhoff-Last E, Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa 2008; 37 (1) 19-30
• 115 Davis SM, Branch DW. Thromboprophylaxis in pregnancy: who and how?. Obstet Gynecol Clin North Am 2010; 37 (2) 333-343
• 116 Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol 2009; 114 (2 Pt 1): 341-353
• 117 Wu O, Robertson L, Twaddle S , et al; Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131 (1) 80-90
• 118 Wu O, Robertson L, Langhorne P , et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94 (1) 17-25
• 119 Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med 2011; 13 (1) 67-76